X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The net proceeds will fund longer toxicology studies and drug manufacturing of SBP-9330, a small molecule that targets a receptor called metabotropic glutamate receptor 2 (mGlu2) to support planned Phase 2 studies for nicotine cessation.
Lead Product(s): SBP-9330
Therapeutic Area: Psychiatry/Psychology Product Name: SBP-9330
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: National Institute on Drug Abuse
Deal Size: $9.0 million Upfront Cash: Undisclosed
Deal Type: Funding February 06, 2024
Details:
The grant will be used for the preclinical development of novel therapeutic options such as positive allosteric modulators (PAMs) of metabotropic glutamate receptor 2 (mGlu2) for the treatment of alcohol use disorder (AUD).
Lead Product(s): Undisclosed
Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: National Institutes of Health
Deal Size: $1.9 million Upfront Cash: Undisclosed
Deal Type: Funding December 07, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
